KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Intangibles: 2020-2024

Historic Intangibles for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $42.1 million.

  • AbCellera Biologics' Intangibles fell 25.21% to $39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.3 million, marking a year-over-year decrease of 25.21%. This contributed to the annual value of $42.1 million for FY2024, which is 65.03% down from last year.
  • AbCellera Biologics' Intangibles amounted to $42.1 million in FY2024, which was down 65.03% from $120.4 million recorded in FY2023.
  • Over the past 5 years, AbCellera Biologics' Intangibles peaked at $161.0 million during FY2021, and registered a low of $42.1 million during FY2024.
  • For the 3-year period, AbCellera Biologics' Intangibles averaged around $98.0 million, with its median value being $120.4 million (2023).
  • In the last 5 years, AbCellera Biologics' Intangibles skyrocketed by 36.80% in 2021 and then tumbled by 65.03% in 2024.
  • Yearly analysis of 5 years shows AbCellera Biologics' Intangibles stood at $117.7 million in 2020, then surged by 36.80% to $161.0 million in 2021, then decreased by 18.31% to $131.5 million in 2022, then fell by 8.42% to $120.4 million in 2023, then slumped by 65.03% to $42.1 million in 2024.